Sat.Jun 29, 2024

article thumbnail

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

PharmaTech

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Leads 52
article thumbnail

EU Leads in Biosimilar Market Access While US Lags Behind, Faces Challenges in Adoption

Pharmacy Times

The European Union (EU) has successfully created a competitive market for biosimilars, while the US faces challenging market dynamics and tactics by pharmacy benefit managers that hinder the adoption of lower-cost therapies.

article thumbnail

Participants for START Pilot Program Selected by FDA

PharmaTech

The seven chosen sponsors will help accelerate development of novel drugs and biologics for rare diseases.

FDA 40